Vaximm Company
Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinical trials in 2011.
Employee Number:
1-10
Headquarters:
Basel, Basel-Stadt, Switzerland, Europe
Founded Date:
2008-01-01
Industry:
Vaccines & Immunotherapy
Super Industry:
Biopharma & Life Science Tools
Phone Number:
+ 49-0621-83-596-8750
Investors:
BB Biotech Ventures, BioMedPartners, Merck, Sunstone Life Science Ventures
Ipo Status:
private
City:
Basel
Region:
Basel-Stadt
Country:
Switzerland
Founders:
Andreas Niethammer, Heinz Lubenau, Klaus Breiner